US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.53 against a street estimate of 0.46 — a beat of 15.2%.
Analysts rate Repligen Corporation a buy (17 buy, 4 hold, 0 sell out of 21) with an average price target of $203.45.
CONFIDENT Record Q3 revenue, strong organic growth and raised 2026 guidance. BioLife adds cell-therapy scale, while filtration timing remains the main near-term weakness. Q3 FY26 Asia Pacific orders reached a record and grew high teens year-to-date; China sales grew over 50% year-to-date. Analysts focused on BioLife integration, filtration timing, equipment orders and future margins. Management emphasized delayed deliveries, strong backlog and early synergy capture. 2026-10-27…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.48% |
| FMR Inc | 5.24% |
| United Capital Financial Advisers Inc | 4.40% |
| Vanguard Capital Management, LLC | 3.80% |
| Vanguard Portfolio Management, LLC | 3.64% |
| Maverick Capital Ltd | 3.13% |
| State Street Corp | 2.84% |
| T. Rowe Price Associates, Inc. | 2.76% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $209.314 million, up from $188.805 million in the third quarter of 2025, an increase of approximate | 2026-10-30 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • Repligen plans to issue $1.0 billion of 0.25% Convertible Senior Notes due 2031, expected to close on or about November 6, 2026, s | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $209.3 million, up 11% as reported and 12.5% organically from $188.8 million. • GAAP results included a $29.5 | 2026-10-27 |
| Acquisition completed · Q4 2026 HEADLINE NUMBERS • Repligen completed its acquisition of BioLife Solutions on October 6, 2026. • BioLife shareholders received, for each BioLife sha | 2026-10-06 |
| Board / officer change · Q3 2026 REPLIGEN CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics provided in this filing BUSINESS & SEGMENT HIGHLIGHTS • Repligen C | 2026-09-15 |
| Company announcement · Q3 2026 REPLIGEN CORPORATION 8-K SUMMARY HEADLINE NUMBERS • Acquisition Price: $11.25 cash plus 0.1442 shares of Repligen common stock per BioLife share • T | 2026-09-08 |
| Quarterly report · Q2 2026 REPLIGEN CORPORATION - 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total Revenue (6 months): $398.4 million, up from $351.5 mil | 2026-07-29 |
| Results announced · Q3 2026 REPLIGEN CORPORATION – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $204 million, up 12% reported / 13% organic year-over-year • Si | 2026-07-28 |
Readable in the app.
| Announcement | Date |
|---|---|
| BioLife merged into Repligen with cash and stock consideration for shareholders Repligen completed its acquisition of BioLife. Each BioLife share was converted into $11.25 in cash plus 0.1442 shares of Repligen common stock, with cash paid for any fractional Repligen sh | 2026-10-06 |
| Agreement and Plan of Merger entered into with subsidiary merger entities Repligen Corporation announced that the HSR (Hart-Scott-Rodino) antitrust waiting period for its acquisition of BioLife Solutions has expired as of September 3, 2026, clearing a major regula | 2026-09-08 |
| Entry into merger agreement with BioLife Solutions announced Repligen Corporation announced on July 22, 2026 that it has agreed to acquire BioLife Solutions, Inc. through a merger agreement signed on July 21, 2026. The deal involves two merger subsidi | 2026-07-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Repligen Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.